Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer

Anti-Cancer Drugs

Volumn 16, Issue 10, 2005, Pages 1129-1134

  Zwitter, M ^a   Kovac, V ^a   Smrdel, U ^a   Kocijancic, I ^a   Segedin, B ^a   Vrankar, M ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Cisplatin; Clinical trial; Gemcitabine; Non small cell lung cancer; Prolonged infusion

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DRUG INFUSION; DRUG TOLERABILITY; FEMALE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HUMAN TISSUE; LEUKOPENIA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY FAILURE; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOEMBOLISM; TOXICITY; TREATMENT INDICATION; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARRHYTHMIA; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; FEMALE; HEART VENTRICLES; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; THROMBOCYTOSIS;

EID: 27644595794     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200511000-00013     Document Type: Article

References (19)

1. Brand R, Capadano M, Tempero M. A phase I trial of weekly gemcitabine administered as prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 1997; 15:331-341.
2. Fossella FV, Lippman SM, Shin DM, Tarassoff P, Calayag-Jung M, Perez-Soler R, et al. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol 1997; 15:310-316.
3. Anderson H, Thatcher N, Walling J, Hansen H. A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br J Cancer 1996; 74:460-462.
4. Akrivakis K, Schmid P, Flath B, Schweigert M, Sezer O, Mergenthaler HG, et al. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study. Anticancer Drugs 1999; 10:525-531.
5. Maurel J, Zorrilla M, Puertolas T, Anton A, Herrero A, Artal A, et al. Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors. Anticancer Drugs 2001; 12:713-717.
6. 2) levels. Invest New Drugs 1997; 15:115-121.
7. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9:491-498.
8. Schmid P, Akrivakis K, Flath B, Grosse Y, Sezer O, Mergenthaler HG, et al. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 1999; 10:625-631.
9. Sezer O, Eucker J, Jakob C, Kaufmann O, Schmid P, Possinger K. Acheivement of complete remission in refractory Hodgkin's disease with prolonged infusion of gemcitabine. Invest New Drugs 2001; 19:101-104.
10. Spath-Schwalbe E, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, Possinger K. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs 2000; 11:325-329.
11. Eckel F, Schmelz R, Erdmann J, Mayr M, Lersch C. Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma. Cancer Invest 2003; 21:690-694.
12. Bass AJ, Gockerman JP, Hammett E, DeCastro CM, Adams DJ, Rosner GL, et al. Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. J Clin Oncol 2002; 20:2995-3000.
13. Rizzieri DA, Bass AJ, Rosner GL, Gockerman JP, DeCastro CM, Petros WP, et al. Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. J Clin Oncol 2002; 20:674-679.
14. Rizzieri DA, Ibom VK, Moore JO, DeCastro CM, Rosner GL, Adams DJ, et al. Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia. Clin Cancer Res 2003; 9:663-668.
15. Kornek GV, Potter R, Selzer E, Schratter A, Ulrich-Pur H, Rogy M, et al. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. Int J Radiat Oncol Biol Phys 2001; 49:665-671.
16. 2 per min) and cisplatin. Cancer Chemother Pharmacol 2002; 50:80-83.
17. Ceribelli A, Gridelli C, De Marinis F, Fabi A, Gamucci T, Cortesi E, et al. Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin. Cancer 2003; 98:337-343.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Ass 1958; 53:457-481.